

Contents

Contributors	xi
Foreword	xiii

Part I History of Wilson Disease

1. History of Wilson Disease

James S. Dooley and Rupert Purchase

Introduction	3
The Definition of Wilson Disease	3
Description of Kayser-Fleischer Rings; Unity of Neurological Definition; Resolving Pseudosclerosis; Liver Disease	5
Corneal Ring	5
Pseudosclerosis	5
Liver Disease	6
Toxin ... Copper	6
Evolution of Diagnostic Tests for Wilson Disease	6
Kayser-Fleischer Rings	6
Tissue Copper	7
Serum Ceruloplasmin	7
Copper as a Therapeutic Target: The Discovery of Drugs for the Treatment of Wilson Disease	7
British Anti-Lewisite	8
D-Penicillamine	8
Trientine (Triethylenetetramine)	8
Zinc Salts	8
Ammonium Tetrathiomolybdate	9
Liver Transplantation	9
Molecular Genetics	9
Cloning of the Wilson Disease Gene <i>ATP7B</i>	10
Function of <i>ATP7B</i>	10
Mutation Analysis	10
Future Directions	10
Conclusion	10

Further Reading on the History of Wilson Disease	11
References	11

Part II Molecular Mechanisms

2. Normal Human Copper Metabolism

Cynthia Abou Zeid and Stephen G. Kaler

Introduction	17
Copper in Human Health	17
Dietary Copper	18
Copper Absorption	18
Copper Transport and Excretion	20
Conclusion	20
References	21

3. *ATP7B* Function

Hannah Pierson and Svetlana Lutsenko

The Biochemical Function of <i>ATP7B</i>	23
Cellular Factors That Affect <i>ATP7B</i> Function	25
Intracellular Trafficking Allows <i>ATP7B</i> to Switch Between the Biosynthetic and Homeostatic Functions	25
Glutaredoxin 1 Interacts With <i>ATP7B</i> and Regulates <i>ATP7B</i> Trafficking	25
Atox1	26
Kinase-Mediated Phosphorylation	27
Tissue Specific Functions of <i>ATP7B</i>	27
<i>ATP7B</i> Role in the Liver	27
<i>ATP7B</i> in Intestine	28
<i>ATP7B</i> in the Brain and Other Tissues	29
Conclusions	29
Acknowledgment	29
References	29

4. Biochemical and Cellular Properties of ATP7B Variants

Samuel Jayakanthan, Courtney McCann and Svetlana Lutsenko

Introduction	33
Molecular Features of ATP7B and Catalytic Cycle	34
Physical Properties of ATP7B Variants	35
Wilson Disease Mutation in Various Domains	44
Mutations in the N-Terminal Domain Are Rare But Have Significant Consequences	44
Actuator (A-Domain) and ATP Binding Domains (ATPBD) Are Major Targets of WD Mutations	45
The H1069Q Mutant	46
The Mutations Within the TM Domain Revealed Long-Range Interactions Between Different Parts of ATP7B	46
Single Nucleotide Polymorphisms May Play a Larger Role in Disease Than Previously Thought	47
Conclusions	48
References	48

5. Animal Models of Wilson Disease

Dominik Huster

Copper Toxicity and Liver Disease in Rodent Models of Wilson Disease	51
Long-Evans Cinnamon Rat	51
LPP Atp7b ^{-/-} Rat	53
Toxic Milk Mouse	53
Toxic Milk Mouse From the Jackson Laboratory (tx-j Mouse)	54
Atp7b ^{-/-} Mouse	55
Other Animal Models for Copper Storage Disorders	56
Dogs With Copper-Associated Hepatitis	56
North Ronaldsay Sheep	57
Conclusion and Research Perspectives	57
Acknowledgment	59
References	59

6. Cellular Copper Toxicity: A Critical Appraisal of Fenton-Chemistry-Based Oxidative Stress in Wilson Disease

Hans Zischka and Josef Lichtmannegger

Introduction	66
Oxidative Stress in WD Patients and Related Animal Models	67

Treating Copper Toxicity in WD Rats	71
Conclusions	77
Acknowledgments	78
References	78

Part III Epidemiology

7. Epidemiology of Wilson Disease

Thomas Damgaard Sandahl and Peter Ott

Introduction	85
Incidence and Prevalence of Wilson Disease	85
The Sardinian Case	85
Prevalence in Other Populations	86
Biochemical Screening for Wilson Disease	87
Population Based Genetic Methods	87
What to Learn From Different Studies of Prevalence?	89
Clinical Presentation	89
Age at Presentation	89
Presenting Phenotype	90
Gender Differences	92
Diagnostic Delay	92
Prognosis of Wilson Disease	92
Acknowledgment	92
References	92

Part IV Diagnosis

8. The Diagnostic Approach to Wilson Disease

Michelle Angela Camarata and Aftab Ala

Establishing a Diagnosis of Wilson Disease	97
The Leipzig Score and Its Utility in Diagnostic Work Up of a Wilson Diagnosis	97
Differential Diagnosis	97
Clinical Features Suggestive of Wilson Disease	
(WD) Diagnosis	99
Liver Disease	100
Neurological/Neuropsychiatric Disease	100
Kayser-Fleischer Rings	100
Other Manifestations	100
Acute Hepatitis and Wilson Disease	100
Investigations	101
Ceruleplasmin	101
Nonceruloplasmin Bound Copper (NCC)	101
Urinary Excretion of Copper	101
Concentration of Copper in the Liver	102
Liver Histology	102

Neuroradiology	102	Alkaline Phosphatase (ALP) to Total Bilirubin (TB) Ratio	135
Molecular Genetic Studies	103	Alkaline Phosphatase (ALP)	136
Family Screening	103	Others	136
References	103	References	136
9. The Genetics of Wilson Disease		12. Liver Pathology of Wilson Disease	
<i>Michelle Angela Camarata and Si Houn Hahn</i>		<i>Hans Peter Dienes and Peter Schirmacher</i>	
ATP7B Gene and ATPase	105	Pathology of Wilson Disease	139
Molecular Structure of ATP7B	105	References	144
ATP7B (P-Type ATPase) Protein Structure	106	13. Neurological Wilson Disease	
Variants in the ATP7B Gene	106	<i>Tomasz Litwin, Petr Dusek and Anna Członkowska</i>	
Regional Gene Frequency	107	Introduction	145
Genotype-Phenotype Correlation	107	Pathophysiology of Neurological WD	
Clinical Molecular Diagnosis	109	Symptoms	145
Population Screening	110	Neurologic Symptoms of WD	147
Conclusion	110	Tremor	147
References	111	Dystonia	148
10. Biochemical Markers		Parkinsonism	149
<i>Aurélia Poujois and France Woimant</i>		Ataxia	149
Traditional Biochemical Markers of Wilson Disease	115	Chorea	150
Ceruloplasmin	115	Dysarthria	150
Serum Copper and Serum Nonceruloplasmin- Bound Copper (NCC)	117	Dysphagia	150
Urinary Excretion of Copper	118	Drooling	150
Liver Biopsy With Copper Determination	118	Gait and Posture Disturbances	150
Exchangeable Copper and REC: New Specific and Sensible Biochemical Markers of Wilson Disease	119	Other, Selected Neurological Symptoms in WD	151
Conclusion	122	Epilepsy	151
References	122	Neuropathies	151
11. Diagnosis of Hepatic Wilson Disease		Restless Leg Syndrome	151
<i>Palittiya Sintusek, Eirini Kyra and Anil Dhawan</i>		Sleep Disturbances	151
Introduction	125	Neurologic Symptoms of Hepatic Encephalopathy (HE) in WD	152
Parameters in the Diagnostic Scoring System	125	Ophthalmologic Signs of WD	152
Ceruloplasmin	125	Neuroimaging in WD	153
Serum Copper	129	Conclusions	154
Urinary Copper	129	References	154
Liver Copper	130	14. Psychiatric Symptoms in WD	
Eye Signs	133	<i>Paula C. Zimbrea</i>	
Coombs-Negative Hemolytic Anemia	133	Introduction	159
Neurological and Psychological Symptoms and Signs	133	Prevalence of Psychiatric Symptoms in WD	159
Genetic ATP7B Mutation Analysis	134	Mood and Anxiety Disorders	159
Proposed Parameters That Facilitate WD Diagnosis	134	Psychotic Disorders	162
AST to ALT Ratio	134	Sleep Disturbances	162
		Other Psychiatric Symptoms	162
		Cognitive Deficits	163
		The Diagnosis of Psychiatric Presentations in WD	163

Laboratory Data and Neuroimaging	164	Social Issues: Real or Effective Nonavailability of Trientine	192
Comment on Genetic Studies	165	Conclusion	192
Significance of Psychiatric Symptoms in WD	165	References	193
Treatment of Psychiatric Symptoms in WD	166		
Conclusion	166		
References	167		
Part V			
Treatment Decisions			
15. General Considerations and the Need for Liver Transplantation			
<i>Michelle Angela Camarata, Karl Heinz Weiss and Michael L. Schilsky</i>			
Introduction	173	18. Tetrathiomolybdate (TTM)	
Liver Transplant in Patients Presenting With ALF as Their Initial Presentation	173	<i>Christian Rupp and Karl Heinz Weiss</i>	
Therapies Used to Bridge Liver Transplant	174	Introduction	197
Liver Transplant in Patients With Established WD	175	Development and Early Clinical Studies	197
Liver Transplantation for Neuropsychiatric Manifestations of WD	176	Bis-Choline TTM (WTX-101)	198
Options for Liver Transplantation in Wilson Disease	176	Pharmacokinetics	198
Auxiliary Liver Grafts	178	Mode of Action	199
Living Donor Liver Transplant	178	Efficacy of Bis-Choline TTM	199
Outcomes Following LT	178	Safety and Tolerability of Bis-Choline TTM	200
Immunosuppression	179	Conclusion	200
Conclusion	180	References	200
References	180		
16. Chelation Therapy: D-Penicillamine			
<i>Peter Ferenci</i>			
Pharmacology	183	19. Zinc Therapy of Wilson Disease	
Drug-Drug Interactions	183	<i>Roderick H.J. Houwen</i>	
Mode of Action	183	Introduction	203
Use of D-Penicillamine in Wilson Disease	184	Mechanism	203
Side Effects	184	Dosage	203
Efficacy	184	Efficacy	203
References	185	Pregnancy	205
		Side Effects	205
		Overtreatment	205
		Combination Therapy	205
		Where Do We Go From Here	206
		References	206
17. Trientine for Wilson Disease: Contemporary Issues			
<i>Eve A. Roberts</i>			
Chemistry	187	20. Symptomatic Treatment of Residual Neurological or Psychiatric Disease	
Pharmacology	188	<i>Ana Vives-Rodriguez and Daphne Robakis</i>	
Therapeutics: Efficacy/Safety	189	Neurological Manifestations	209
Adverse Effects	190	Parkinsonism	209
Emerging Applications	190	Dystonia	210
		Treatment Options in Dystonia	210
		Botulinum Toxin	211
		Oral Medications	211
		Surgical Treatment for Dystonia	211
		Tremor	211
		Propranolol	212
		Primidone	212
		Cerebellar Ataxia	213
		Cognitive Impairment	213
		Psychiatric Manifestations	213
		Conclusion	214
		References	214

21. Other Treatment Regimens and Emerging Therapies

Christian Rupp and Karl Heinz Weiss

Response Guided Therapy	217
Other Drugs	217
Acid Sphingomyelinase	217
Curcumin	218
Chinese Herbal Medicines	218
Plant Decapeptide OSIP108	218
Methanobactin	218
Therapeutic Plasma Exchange (TPE)	218
Mutation Specific Therapy	218
Gene Transfer	219
Hepatocyte/Tissue Transfer	219
References	219

Part VI Monitoring

22. Monitoring of Medical Therapy and Copper End Points

France Woimant and Aurélie Poujois

The Initial Phase	223
Frequency of the Follow Up	224
Clinical Follow Up	224
Biological Monitoring (Except Cupric Assessment)	225
Copper Monitoring	225
The Maintenance Phase	226
Frequency of Follow Up During the Maintenance Phase	227
Clinical Follow Up	227

Biological Monitoring (Except Cupric Assessment)	228
Copper Monitoring	228
Other Noninvasive Assessment of Wilson Disease	228
Red Flags	229
Conclusions	230
References	230

Part VII Main Challenges in Diagnosis and Treatment

23. Special Treatment Considerations for Wilson Disease

Michelle Angela Camarata, Karl Heinz Weiss and Michael L. Schilsky

Treatment Choices and Their Influence on the Monitoring of Therapy for Outcome and Safety	235
Hepatic	235
Neurologic	237
Monitoring Copper Parameters on Treatment	239
What Constitutes Treatment Failure?	240
Alternative Reasons for Changing Therapy	241
Earliest Age for Initiating Treatment	242
Treatment in Pregnancy	243
References	243

Index	247
-------	-----